{"id":32934,"date":"2025-02-13T10:25:36","date_gmt":"2025-02-13T10:25:36","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=32934"},"modified":"2025-02-13T14:50:56","modified_gmt":"2025-02-13T14:50:56","slug":"newronika-secures-e13-6-million-series-b-funding-to-advance-adaptive-dbs-platform","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/newronika-secures-e13-6-million-series-b-funding-to-advance-adaptive-dbs-platform\/","title":{"rendered":"Newronika Secures \u20ac13.6 Million Series B Funding to Advance Adaptive DBS Platform"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/newronika\/\" target=\"_blank\" rel=\"noreferrer noopener\">Newronika<\/a>, a global leader in advanced deep brain stimulation (DBS) technology, has successfully closed a \u20ac13.6 million Series B funding round. The investment was led by Fondazione ENEA Tech e Biomedical, with participation from existing investors including Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This funding will accelerate the development and commercialization of Newronika\u2019s innovative adaptive DBS platform, designed to deliver precision therapy for Parkinson\u2019s disease patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Newronika\u2019s adaptive DBS system represents a paradigm shift in neuromodulation, leveraging real-time neural data and machine learning to provide personalized therapy. Unlike traditional DBS systems, which deliver continuous stimulation, Newronika\u2019s platform dynamically adjusts therapy based on patients\u2019 neural activity, improving symptom relief while minimizing side effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The funding will support the expansion of clinical validation efforts, advance product pipelines, and enable strategic collaborations to strengthen Newronika\u2019s position at the forefront of medical device innovation. The company\u2019s momentum is further underscored by recent milestones, including a grant from The Michael J. Fox Foundation and IDE approval for its adaptive DBS system.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis Series B round validates our commitment to transforming deep brain stimulation,\u201d said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika. \u201cBy integrating real-time neural data and machine learning, we aim to deliver therapies that surpass the capabilities of existing devices, improving outcomes for patients worldwide.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Maria Cristina Porta, General Manager of ENEA Tech e Biomedical, added, \u201cNewronika\u2019s adaptive DBS platform has the potential to revolutionize the treatment of movement disorders. Their innovative approach aligns with our mission to support disruptive medical technologies that improve health and drive economic value.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Davide Turco, CEO of Indaco, emphasized, \u201cWe are proud to continue supporting Newronika as they advance their adaptive DBS system, which promises to enhance the quality of life for Parkinson\u2019s patients.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis funding round solidifies Newronika\u2019s strategic vision and commitment to pushing the boundaries of DBS technology,\u201d said Claudio Giuliano, Chairman of Newronika. \u201cWe are dedicated to leading the evolution of neuromodulation and delivering next-generation solutions to patients in need.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With this investment, Newronika is poised to accelerate the development of its adaptive DBS platform, bringing personalized, real-time neuromodulation to patients globally and transforming the treatment of Parkinson\u2019s disease and other movement disorders.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Newronika has closed a \u20ac13.6 million Series B funding round to accelerate the development of its adaptive DBS platform. The investment, led by Fondazione ENEA Tech e Biomedical, will support clinical validation, commercialization, and innovation in personalized deep brain stimulation for Parkinson\u2019s disease.<\/p>\n","protected":false},"author":2,"featured_media":32936,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[488,681,6,10,671],"tags":[594],"class_list":["post-32934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","category-care-therapy","category-europe","category-strategic-development","category-top-news","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/32934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=32934"}],"version-history":[{"count":1,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/32934\/revisions"}],"predecessor-version":[{"id":32935,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/32934\/revisions\/32935"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/32936"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=32934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=32934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=32934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}